Fertility Preservation Strategies in Women’s Health: Evidence-Based Approaches and Clinical Considerations

Abstract

Fertility preservation has emerged as a critical component in women’s health, particularly in the context of increasing cancer survival rates and delayed childbearing. This review synthesizes recent scientific evidence on fertility preservation strategies, elucidates their mechanisms, and provides clinicians with a practical framework for individualized patient care. Emphasis is placed on epidemiology, pathophysiology, risk factors, clinical presentation, diagnostic criteria, established and emerging preservation options, and guideline-driven recommendations, with an aim to optimize reproductive outcomes in women facing gonadotoxic therapies or other fertility-compromising conditions.

Introduction

The ability to preserve fertility is a growing concern in contemporary women’s health, driven by rising cancer survivorship, postponement of childbearing, and the increased prevalence of conditions such as endometriosis and autoimmune diseases. Advances in reproductive medicine have expanded the spectrum of fertility preservation options, yet optimal selection remains challenging, necessitating a thorough understanding of patient-specific factors, underlying pathophysiology, and current guideline recommendations.

Epidemiology / Disease Burden

Globally, an estimated 1.7 million women are diagnosed with cancer annually during their reproductive years, with breast cancer constituting the majority. Up to 10% of women with systemic autoimmune diseases such as lupus require immunosuppressive therapies with potential gonadotoxicity. Additionally, societal trends toward delayed childbearing have led to a significant rise in age-related infertility, affecting approximately 15% of couples worldwide. The demand for fertility preservation is expected to increase further as survival rates improve and awareness grows.

Pathophysiology

The female ovarian reserve is finite, comprising a fixed population of primordial follicles that decline with age and are susceptible to iatrogenic injury. Chemotherapeutic agents particularly alkylating agents and pelvic irradiation cause DNA damage, follicular apoptosis, and stromal fibrosis, leading to diminished ovarian reserve or premature ovarian insufficiency (POI). Similarly, surgical interventions for endometriosis or ovarian cysts may inadvertently reduce ovarian reserve by excising healthy tissue or disrupting blood supply. Autoimmune oophoritis, genetic syndromes, and environmental exposures further contribute to oocyte loss through immune-mediated destruction or direct cytotoxic mechanisms.

Risk Factors

Key risk factors for fertility impairment include young age at cancer diagnosis, need for high-dose or prolonged chemotherapy, pelvic or total body irradiation, underlying genetic predispositions (e.g., BRCA mutations, Turner syndrome), extensive endometriosis, prior ovarian surgery, and concomitant use of gonadotoxic medications. Individual susceptibility varies with baseline ovarian reserve, treatment regimens, and comorbidities. Accurate risk stratification is essential to guide timely fertility preservation referrals and interventions.

Clinical Features

Women at risk for fertility loss may initially be asymptomatic, with declining ovarian reserve detected only via biochemical markers (e.g., anti-Müllerian hormone [AMH], follicle-stimulating hormone [FSH]) and antral follicle count (AFC) on ultrasound. Menstrual irregularities, amenorrhea, and signs of estrogen deficiency (e.g., hot flashes, vaginal dryness) typically manifest with advanced depletion. In cancer survivors, these symptoms may be confounded by treatment effects or comorbidities, necessitating a high index of suspicion and proactive screening.

Diagnosis

Assessment of fertility potential hinges on comprehensive evaluation, including detailed history, reproductive goals, and risk exposure. Laboratory investigations should include serum AMH, FSH, estradiol, and inhibin B levels, complemented by transvaginal ultrasonography for AFC estimation. Genetic counseling may be indicated for those with familial syndromes or recurrent premature ovarian insufficiency. Multidisciplinary input involving reproductive endocrinologists, oncologists, and geneticists enhances diagnostic accuracy and intervention planning.

Treatment & Management

Fertility preservation strategies are tailored to individual risk profiles, urgency of treatment, and reproductive intentions. Established modalities include oocyte and embryo cryopreservation, ovarian tissue cryopreservation, and gonadotropin-releasing hormone (GnRH) agonist co-treatment. Oocyte and embryo vitrification are first-line options for postpubertal women with sufficient time for controlled ovarian stimulation (COS). Ovarian tissue cryopreservation is preferred for prepubertal girls or when immediate gonadotoxic therapy is required. GnRH agonists may offer ovarian protection in selected patients, though efficacy remains debated. Surgical approaches such as ovarian transposition (oophoropexy) are considered prior to pelvic irradiation. Counseling on realistic success rates, risks of delay, and experimental nature of some techniques is critical.

Recent Advances / Emerging Therapies

Technological innovations have significantly improved outcomes in oocyte and tissue cryopreservation, with vitrification yielding higher survival and implantation rates. Artificial ovary constructs, in vitro follicle maturation, and stem cell-derived gametogenesis are under active investigation, holding promise for women with absent or severely depleted ovarian reserve. Fertoprotective agents targeting molecular pathways of follicular apoptosis and DNA repair are being explored in preclinical and early-phase clinical studies. Additionally, oncofertility navigators and digital decision aids have enhanced patient engagement and timely intervention.

Guideline Recommendations

Major societies, including the American Society of Clinical Oncology (ASCO), American Society for Reproductive Medicine (ASRM), and European Society of Human Reproduction and Embryology (ESHRE), endorse early fertility preservation counseling for all at-risk women prior to initiation of gonadotoxic therapies. Oocyte and embryo cryopreservation are recommended as standard-of-care, while ovarian tissue cryopreservation is considered no longer experimental. Shared decision-making, individualized risk assessment, and multidisciplinary collaboration are strongly advocated. Ongoing surveillance post-intervention is advised to monitor ovarian function and reproductive outcomes.

Conclusion

Fertility preservation is an integral aspect of comprehensive women’s healthcare, mandating prompt, evidence-based interventions tailored to patient-specific risk profiles and reproductive goals. Advances in cryopreservation and emerging biotechnologies have expanded the therapeutic armamentarium, improving the potential for future biological parenthood. Clinicians must remain abreast of evolving guidelines and facilitate multidisciplinary care to optimize reproductive and psychosocial outcomes for women at risk of fertility loss.